Abstract
Molecular-targeted therapy has the great benefit of a cytoreductive effect against metastatic renal cell carcinoma. However, a complete response is rare, and most patients usually experience progression of metastases during molecular-targeted therapy. Complete resection of metastases has been reported to improve survival in patients with metastatic renal cell carcinoma. Our report presents the possibility of improved clinical outcomes after complete resection of lung metastases, even in patients with progression of metastases in bilateral lung fields. Furthermore, the continuation of systemic therapies with cytokines or molecular-targeted agents may be unnecessary after complete resection of lung metastases. Pulmonary resection offers opportunities to improve quality of life, reduce medical costs, and increase survival in renal cell carcinoma patients with lung metastases.
| Original language | English |
|---|---|
| Pages (from-to) | 941-949 |
| Number of pages | 9 |
| Journal | Japanese Journal of Chest Diseases |
| Volume | 74 |
| Issue number | 9 |
| Publication status | Published - 01-09-2015 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine